MedTrace Logo

Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?

NCT05923970 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-03-16

No results posted yet for this study

Summary

The current recommendation for a full course of measles-mumps-rubella-(varicella) vaccine (MMR(V)) is two doses. The problem is, many individuals within the vaccinated cohort show antibody levels that are below the level considered to be protective, even after two doses of vaccine. Because of these waning antibody levels, it is currently unknown whether highly vaccinated populations are protected from infection against measles, mumps, rubella, or varicella should they be exposed to any of these viruses. The uncertainty of a woman's immune status is partly due to the type of testing that is used to indicate protection. While immunity to viral infection requires both a humoral and a cell mediated immune (CMI) response, only humoral (antibody) responses are measured routinely in the laboratory. This study will examine CMI responses and the role of a third dose of vaccine for previously vaccinated women whose antibody levels are below the cut off. This study will not administer vaccine, but rather will include women who have received a third dose of vaccination through routine health care follow up in the study cohort.

Conditions

  • Vaccination Failure
  • Vaccine Response Impaired

Interventions

DIAGNOSTIC_TEST

Serology for antibody levels - Baseline

Measurement of rubella IgG antibody levels at baseline

DIAGNOSTIC_TEST

Serology to assess cell mediated immune (CMI) response - Baseline

Assessment of cell mediated immune (CMI) response to measles, mumps, rubella, and varicella at baseline.

DIAGNOSTIC_TEST

Serology for antibody levels - Post third dose of MMR vaccine

Measurement of rubella IgG antibody levels post third dose of MMR vaccine

DIAGNOSTIC_TEST

Serology to assess CMI - Post third dose of MMR vaccine

Assessment of cell mediated response (CMI) to measles, mumps, rubella, and varicella post third dose of MMR vaccine.

Sponsors & Collaborators

  • Merck Canada Inc.

    collaborator INDUSTRY

  • University of Alberta

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-09
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05923970 on ClinicalTrials.gov